Trial Profile
Phase I Study of Nilotinib Given With Radiation For Patients With High Risk Chordoma.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Chordoma
- Focus Adverse reactions
- 31 May 2020 Results of phase I study of nilotinib plus radiation (RT) in high-risk chordoma presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 03 Mar 2020 Planned End Date changed from 1 Dec 2019 to 1 Dec 2025.
- 11 Dec 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.